NASDAQ:CCCC
C4 Therapeutics Inc Stock News
$5.48
-0.0900 (-1.62%)
At Close: May 24, 2024
Zacks Investment Research Lowers C4 Therapeutics (NASDAQ:CCCC) to Hold
11:04am, Saturday, 20'th Nov 2021 Dakota Financial News
Zacks Investment Research lowered shares of C4 Therapeutics (NASDAQ:CCCC) from a buy rating to a hold rating in a report published on Wednesday, Zacks.com reports. According to Zacks, C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the bodys natural regulation of protein levels to develop novel therapeutic candidates to target and []
C4 Therapeutics (NASDAQ:CCCC) Lifted to Buy at Zacks Investment Research
10:08am, Friday, 19'th Nov 2021 Dakota Financial News
Zacks Investment Research upgraded shares of C4 Therapeutics (NASDAQ:CCCC) from a hold rating to a buy rating in a research report released on Monday, Zacks.com reports. The firm currently has $47.00 target price on the stock. According to Zacks, C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the bodys natural regulation []
Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season
09:57am, Wednesday, 10'th Nov 2021
C4 Therapeutics (CCCC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
C4 Therapeutics Multiple Myeloma Candidate Scores FDA Orphan Drug Tag
06:39am, Thursday, 12'th Aug 2021
The FDA has granted Orphan Drug Designation to C4 Therapeutics Inc (NASDAQ: CCCC) CFT7455 for multiple myeloma. CFT7455 is an orally bioavailable MonoDAC degrader targeting IKZF1/3.
C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
04:02pm, Wednesday, 11'th Aug 2021
– Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expected in 2022 –
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma
04:01pm, Wednesday, 11'th Aug 2021
WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selec
WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selec
C4 Therapeutics Announces Pricing of Public Offering
07:51pm, Wednesday, 16'th Jun 2021
WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selec
C4 Therapeutics Launches Proposed Public Offering
04:12pm, Monday, 14'th Jun 2021
WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selec
C4 Therapeutics Appoints Lauren White as Chief Financial Officer
04:01pm, Thursday, 20'th May 2021
WATERTOWN, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy d
C4 Therapeutics to Present at Upcoming Investor Conferences
07:00am, Wednesday, 12'th May 2021
WATERTOWN, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy d
– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models –
C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results
04:01pm, Thursday, 11'th Mar 2021
– Phase 1/2 Trial for Lead Candidate CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3 for the Treatment of Hematologic Malignancies, On Track for 1H 2021 Initiation Following FDA Clearance of Invest
WATERTOWN, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy
C4 Therapeutics to Participate in Upcoming March Investor Conferences
07:00am, Wednesday, 24'th Feb 2021
WATERTOWN, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy